Hepatitis B virus genotypes and response to antiviral therapy

Clinical Laboratory

Volumn 52, Issue 1-2, 2006, Pages 43-47

  Enomoto, Masaru ^a   Tamori, Akihiro ^a   Nishiguchi, Shuhei ^b  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Adefovir; Antiviral therapy; Genotype; Hepatitis B; Interferon; Lamivudine

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; ENTECAVIR; LAMIVUDINE; NUCLEOTIDE DERIVATIVE; PEGINTERFERON ALPHA2B;

ANTIVIRAL ACTIVITY; ASIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; GENETIC VARIABILITY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; GERMANY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; NONHUMAN; NORTH AMERICA; PACIFIC ISLANDS; PREDICTION; PUBLIC HEALTH; REVIEW; RISK FACTOR; SEROCONVERSION; TREATMENT DURATION; TREATMENT OUTCOME; WESTERN EUROPE;

ADENINE; ANTIVIRAL AGENTS; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; PHOSPHONIC ACIDS;

HEPATITIS B VIRUS;

EID: 32644460117     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Maddrey WC. Hepatitis B - an important public health issue. Clin Lab 2001; 47: 51-5.
2. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.
3. de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A, Paumgartner G, Pietrangelo A, Rodes J, Rosenberg W, Valla D; EASL Jury. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003;39 (Suppl 1): S3-25.
4. Lok AS, McMahon BJ; Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 857-61.
5. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711-3.
6. Kohmoto M, Enomoto M, Yano Y, Otani S, Minamitani S, Tamori A, Habu D, Takeda T, Shiomi S, Seki S, Arakawa T, Nishiguchi S. Detection of serum hepatitis B virus DNA by real-time quantitative polymerase chain reaction (TaqMan PCR) during lamivudine treatment: comparison with three other assays. Hepatol Res 2003; 26: 125-33.
7. Enomoto M, Nishiguchi S, Seki S, Yamane T, Hino M. Adefovir dipivoxil to prevent exacerbation of lamivudine-resistant heaptitis B infection during chemotherapy for non-Hodgkin's lymphoma. Am J Gastroenterol. 2004; 99: 1619-20.
8. Pas SD, Noppornpanth S, van der Eijk AA, de Man RA, Niesters HG. Quantification of the newly detected lamivudine resistant YSDD variants of Hepatitis B virus using molecular beacons. J Clin Virol 2005; 32: 166-72.
9. Le Bouvier GL, McCollum RW, Hierholzer WJ Jr, Irwin GR, Krugman S, Giles JP. Subtypes of Australia antigen and hepatitis-B virus. JAMA 1972; 222: 928-30.
10. Courouce AM, Drouet J, Muller JY. Australia antigen subtypes identification. Bibl Haematol. 1976; 42: 89-127.
11. Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y, Mayumi M. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 1988; 69: 2575-83.
12. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994; 198: 489-503.
13. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, Rossau R. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000; 81: 67-74.
14. Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002; 83: 2059-73.
15. Norder H, Courouce AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, Robertson BH, Locarnini S, Magnius LO. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004; 47: 289-309.
16. Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, Ishida T, Chutaputti A, Lai CL, Ueda R, Miyakawa Y, Mizokami M. Hepatitis B virus of genotype B with or without recombinetion with genotype C over the precore region plus the core gene. J Virol 2002; 76: 5985-92.
17. Thakur V, Guptan RC, Kazim SN, Malhotra V, Sarin SK. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J Gastroenterol Hepatol 2002; 17: 165-70.
18. Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, Okanoue T, Yotsuyanagi H, Iino S. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 2001; 33: 218-23.
19. Zhang X, Zoulim F, Habersetzer F, Xiong S, Trepo C. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic heaptitis B. J Med Virol 1996; 48: 8-16.
20. Erhardt A, Blondin D, Hauck K, Sagir A, Kohnle T, Heintges T, Haussinger D. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54: 1009-13.
21. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 998-1002.
22. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg (+) chronic hepatitis than genotype C. Hepatology 2002; 36: 1425-30.
23. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW; HBV 99-01 Study Group; Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-9.
24. Zöllner B, Petersen J, Schroter M, Laufs R, Schoder V, Feucht HH. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 2001; 357: 934-5.
25. Zöllner B, Petersen J, Puchhammer-Stockl E, Kletzmayr J, Sterneck M, Fischer L, Schroter M, Laufs R, Feucht HH. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 2004; 39: 42-50.
26. Buti M, Cotrina M, Valdes A, Jardi R, Rodriguez-Frias F, Esteban R. Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine? J Hepatol 2002; 36: 445-6.
27. Kao JH, Liu CJ, Chen DS. Hepatitis B viral genotypes and lamivudine resistance. J Hepatol 2002; 36: 303-4.
28. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38: 1267-73.
29. Akuta N, Suzuki F, Kobayashi M, Tsubota A, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 2003; 38: 315-21.
30. Westland C, Delaney W 4th, Yang H, Chen SS, Marcellin P, Hadziyannis S, Gish R, Fry J, Brosgart C, Gibbs C, Miller M, Xiong S. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 2003; 125: 107-16.